Latest National Cancer Institute Stories
High-dose supplementation with both the trace element selenium and vitamin E can increase the risk of prostate cancer in some men, according to a new multi-center study appearing in Friday’s edition of the Journal of the National Cancer Institute.
Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase, will be investigated in combination with rituximab by the ECOG-ACRIN Cancer Research Group in its latest clinical trial, E1912.
Cadillac is Host Sponsor for dinner to raise money for chemotherapy unit renovation DETROIT, Feb.
OriGene Technologies, Inc.
The Meso Foundation commends nineteen Members of the House of Representatives, led by Betty McCollum (D-MN) and Chellie Pingree (D-ME), for sending a letter to the Director of the National Cancer
Allegheny Health Network and Johns Hopkins Medicine announced today that they have signed a memorandum of understanding to seek to establish a formal affiliation between Allegheny and the Johns
Blinatumomab, the first BiTE® antibody to be developed for the treatment of cancer, is being investigated by the ECOG-ACRIN Cancer Research Group in its latest trial, E1910. Philadelphia,
Using a nomogram that incorporates age, Gleason score, and prostate-specific antigen (PSA) level at diagnosis, individual risks that a screen-detected prostate cancer has been overdiagnosed can be estimated.
The Annual Report to the Nation on the Status of Cancer, covering the period 1975–2010, showed death rates for lung cancer, which accounts for more than one in four cancer deaths, dropping at a faster pace than in previous years.
A Phase I trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe, with early evidence for anti-tumor activity.
- Large; stout; burly.